Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine and Hemorrhage Tolerance
NCT04138615Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hemorrhagic shock and pain comparing Morphine Arm with Placebo Arm (2 arms). Primary endpoint: Tolerance to Simulated Hemorrhage at 30 minutes. Started Nov 2019; status: completed.
02
Drugs
morphine
03
Conditions
hemorrhagic shockpain
Beyond the preview
Go deeper on NCT04138615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138615.